Abstract

Background: Since the first official report of SARS-CoV-2 infection in Iran on 19 February 2020, our country has been one of the worst affected countries by the COVID-19 epidemic in the Middle East. In addition to demographic and clinical characteristics, the number of hospitalized cases and deaths is an important factor for evidence-based decision-making and disease control and preparing the healthcare system to face the future challenges of COVID-19. Therefore, this cohort study was conducted to determine the demographics, clinical characteristics, and outcomes of hospitalized COVID-19 patients in Kermanshah Province, west of Iran.

Methods: This multicenter retrospective cohort study included all suspected, probable, and confirmed cases of COVID-19 hospitalized in Kermanshah Province, Iran during the first year of the COVID-19 pandemic. Demographics, clinical characteristics, outcomes and other additional information of hospitalized patients were collected from the COVID-19 database of the Medical Care Monitoring Center (MCMC) of Kermanshah Province.

Results: Kermanshah Province experienced three waves of COVID-19 infection considering the hospitalization and mortality rates between February 20, 2020 and February 19, 2021. A total of 27,256 patients were included in the study: 5,203 (19.09%) subjects were suspected, 9,136 (33.52%) were probable, and 12,917 (47.39%) were confirmed COVID-19 cases. The mean age of the patients was 53.34 ± 22.74 years and 14,648 (53.74%) were male. The median length of hospital stay among COVID-19 survivors and non-survivors patients were 4 (interquartile range [IQR] 1–6) and 4 (IQR 1–8) days, respectively. Among patients with COVID-19, 2,646 (9.71%) died during hospitalization. A multivariable logistic regression revealed that odds of death among patients ≥ 85 years was significantly greater than among patients < 15 years (adjusted odds ratio [aOR] 4.79, 95% confidence interval [CI] = 3.43–6.71, p ≤ 0.001). Patients with one (aOR 1.38, 95% CI 1.21–1.59, p = 0.04), two (aOR 1.56, 95% CI 1.27–1.92, p = 0.001) or more (aOR 1.50, 95% CI 1.04–2.17, p = 0.03) comorbidities had higher odds of in-hospital death compared to those without comorbidities. The male sex (aOR 1.20, 95% CI 1.07–1.35, p = 0.002), ICU admission (aOR 4.35, 95% CI 3.80–4.97, p < 0.001), intubation...
Background
At the end of 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in Wuhan, the capital of Hubei Province, Central China [1]. The disease rapidly spread across China and the world and became a major health concern on a global scale. It has a broad spectrum of clinical manifestations from flu-like symptoms such as fever, cough, anosmia, headache, myalgia and gastrointestinal symptoms to severe acute respiratory failure, renal failure, and need for hemodynamic support [2]. While most the infected patients have mild symptoms and some may even be asymptomatic, approximately 3–5% of the patients will require hospitalization [3]. However, the exact rates differ per country. Bacterial and fungal co-infection in COVID-19 patients also remain a life-threatening condition [4].

The first two cases of COVID-19 in Iran were reported in Qom Province on February 19 [5]. Afterward, a wave of the pandemic outbreak hit the country. During the earliest months of the COVID-19 outbreak, the adjusted seroprevalence was 17.1% (95% CI 14.6–19.5) ranging from 72.6% (95% CI 53.9–92.8) to 1.7% (95% CI 0.0–6.0) in a population-based seroprevalence study using sera samples obtained from 3530 individuals from the general population from 18 cities from 17 provinces in country[6]. Despite the economic crisis in Iran, it has taken important steps to combat COVID-19 since the earliest days of the pandemic [7, 8]. Nevertheless, the increasing number of patients with COVID-19 has increased the demand for hospitalization and admission to the intensive care unit (ICUs). The emergency preparedness in terms of hospital beds, skilled health workers, reserves of personal protective equipment and consumables and pharmaceuticals differs markedly between countries, which can lead to differences in mortality rates.

Several studies have investigated the risks factors and mortality rates of SARS-CoV-2 infection [9–12], but there is a lack of comprehensive data from Iran as one of the important epicenters of the COVID-19 pandemic in the Middle East. These data allow authorities to assess the risk factors, strategies, and infection control practices. Thus, this observational study was conducted to describe the demographics, clinical characteristics and outcomes of COVID-19 patients admitted to the hospitals of Kermanshah Province, West of Iran during a one-year period.

Methods
Setting and study design
Kermanshah Province is one of the 31 provinces of Iran located in the west of the country bordering Iraq. According to the 2017 census, it is the 13th most populated province in Iran with a population of 1,952,434. Kermanshah Province comprises 14 counties including Kermanshah, Dalahu, Gilan-e Gharb, Harsin, Esalamabad-e Gharb, Javanrud, Kangavar, Paveh, Qasr-e Shirin, Ravansar, Sahneh, Sarpol-e Zahab, Salas-e Babajani, and Sonqor. Kermanshah Province, as the center of medical treatment in the west of the country, covers many patients from adjacent provinces as well as Iraq every year.

In this retrospective, multicenter cohort study, we enrolled all patients who were hospitalized with SARS-CoV-2 infection to 2 treatment centers and 25 hospitals (8 university hospitals, 10 governmental hospitals, 2 private hospitals, 3 military hospitals, and 2 hospitals affiliated to other organizations) in Kermanshah Province, Iran, between February 20, 2020 and February 19, 2021. All hospitals were supervised by KUMS (Kermanshah University of Medical Sciences) during the COVID-19 pandemic. All hospitalized patients were followed-up until they were either discharged or died.

The inclusion criterion was hospitalization with suspected, probable or confirmed diagnosis of COVID-19 during the study period. It should be noted that only cases with moderate to severe COVID-19 (peripheral oxygen saturation (SpO2) of 93% or less in room air and/or an absolute lymphocyte count of<1100/μl, blood pressures (BPs)<90 mmHg or decreased level
of consciousness) were admitted to the hospital as per guidelines issued by Iran Ministry of Health and Medical Education (MOHME). The subjects that lacked a positive RT-PCR test, positive computed tomography (CT) findings, and congruent symptoms were excluded from the study. In addition, patients with duplicate records based on name, ID number and gender were excluded.

Study definitions
According to guidelines issued by the MOHME, COVID-19 patients were classified as suspected, probable, or confirmed cases. Briefly, the suspected COVID-19 cases were defined as those having symptoms such as fever, cough or acute respiratory illness. Probable cases were defined as suspected cases that had chest CT scan showing findings of COVID-19 disease. Confirmed cases were defined as individuals with a positive real-time RT-PCR test or nucleic acid sequencing for the SARS-CoV-2 virus based on nasopharyngyal swab samples with/without typical radiological findings. The history of exposure to SARS-CoV-2 was defined as having any close contacts with a confirmed or probable COVID-19 case in the 14 days prior to onset of symptoms. Re-infection with COVID-19 was defined as a person was infected (got sick) once, recovered, and then later became infected again. The history of exposure to SARS-CoV-2 and re-infection with COVID-19 was assessed by questioning the patient.

Data sources and collection
At the beginning of the COVID-19 epidemic, Iranian MOHME set up Medical Care Monitoring Center (MCMC) information system for reporting hospitalized COVID-19 patients. All suspected, probable, and confirmed case data in Kermanshah Province were daily recorded on the national registry of COVID-19 database according to Iranian MOHME guideline. In this portal, demographic variables such as age and sex, self-reported history of comorbidity (including hypertension, cardiovascular disease, immunodeficiency, cancer, pulmonary disease, etc.), smoking status, drug addiction, pregnancy, history of exposure to SARS-CoV-2, and previous COVID-19 infection registered for each patient. In addition, this portal included self-reported symptoms including symptom onset to hospital admission (including respiratory distress, fever, cough, muscular pain, anorexia etc.), chest CT scan report, RT-PCR result, intubation, ICU admission and in-hospital outcome (death or discharge). In this multi-centre study, the data of all COVID-19 patients who had visited COVID-19 designated healthcare facilities across the province of Kermanshah were extracted from the KUMS integrated MCMC web-based database. The data from all designated hospitals for COVID-19 in province were registered in the portal in the same format and the central office in KUMS had access to all records anytime.

Statistical analysis
Continuous variables were expressed as means ± standard deviation (SD) or median and interquartile range (IQR). Categorical variables were presented as frequencies and percentages. Univariate and backward stepwise multivariate logistic regression models were performed to estimate the association between clinical and demographic characteristics of COVID-19 patients with inhospital mortality. Variables from univariate models with p < 0.2 were included in a backward stepwise logistic regression model (comorbidities together are considered in the model). Results from the multivariate logistic model are presented as adjusted OR (aOR) with 95% confidence interval [13] and p-value. All p-values of < 0.05 were considered statistically significant. Statistical analysis was performed using Stata version 14.1 software (Stata Corp, College Station, TX, USA).

Results
During a 1-year period, 28,996 patients with SARS-CoV-2 infection were admitted to the designated hospitals, of whom 809 patients were excluded due to duplicate records based on the name, ID number, time of admission, hospital, and 931 patients were excluded due to lack of PCR-confirmed SARS-CoV-2, CT scan and congruent symptoms. Finally, 27,256 COVID-19 patients with a mean age of 53.34 ± 22.74 years (median, IQR: 57, 38–70) were included in the study (53.74% male and 46.26% female). Of all patients, 11,002 (40.37%) were in the age group 60–85 years. Table 1 shows the demographic and clinical characteristics of 27,256 patients included in this study.

Clinical presentation on admission and comorbidities
In total, 5203 (19.09%) subjects were suspected, 9136 (33.52%) were probable, and 12,917 (47.39%) were confirmed COVID-19 cases. The most common symptoms in the time of admission were respiratory respiratory distress (65.58%), cough (41.37%), fever (30.88%), and muscle pain (25.63%). Approximately one-fifth of COVID-19 patients (18.22%) had one comorbidity, and the most common comorbidities were hypertension (12.65%), cardiovascular disease (7.62%), diabetes (7.36%), and cancer (2.04%) (more details in Table 1).

Geographical distribution of hospitalization and mortality
Figure 1 shows map the distribution of hospitalized COVID-19 patients based on county of residence. According to the results, the frequency of hospitalized COVID-19 patients in Kermanshah Province was 1312
Table 1  Clinical and demographic characteristics for 27,256 cases involved in this study by mortality

| Variable                                         | Total N (%) (n = 27,256) | Died N (%) (n = 2646) |
|--------------------------------------------------|--------------------------|-----------------------|
| **Gender**                                       |                          |                       |
| Male                                             | 14,648 (53.74)           | 1533 (57.94)          |
| Female                                           | 12,608 (46.26)           | 1113 (42.06)          |
| **Age (Years)**                                  |                          |                       |
| < 15                                             | 2122 (7.79)              | 102 (3.85)            |
| 15–45                                            | 6635 (24.34)             | 240 (9.07)            |
| 45–60                                            | 5893 (21.63)             | 403 (15.23)           |
| 60–85                                            | 11,002 (40.37)           | 1568 (59.26)          |
| > 85                                             | 1604 (5.88)              | 333 (12.59)           |
| **Dwelling place**                               |                          |                       |
| Provincial capital                               | 13,487 (49.48)           | 1579 (59.67)          |
| Outside provincial capital                       | 12,987 (47.65)           | 1002 (37.87)          |
| Other provinces                                  | 782 (2.87)               | 65 (2.46)             |
| **History of contact with a case of COVID-19 in**|                          |                       |
| the last 14 days                                 | 13,826 (50.72)           | 1377 (52.04)          |
| **Re-infection with COVID-19**                   | 226 (0.82)               | 28 (1.54)             |
| **Smoking**                                      | 666 (2.44)               | 64 (2.42)             |
| **Drug addiction**                               | 539 (1.97)               | 53 (2)                |
| Pregnancy                                        | 260 (0.95)               | 1 (0.04)              |
| **Presenting symptoms**                          |                          |                       |
| Respiratory distress                             | 17,875 (65.58)           | 1894 (71.53)          |
| Cough                                            | 11,276 (41.37)           | 764 (28.85)           |
| Fever                                            | 8417 (30.88)             | 542 (20.47)           |
| Muscle pain                                      | 6987 (25.63)             | 502 (18.96)           |
| Anorexia                                         | 1947 (7.14)              | 163 (6.24)            |
| Headache                                         | 1550 (5.68)              | 62 (2.38)             |
| Loss of consciousness                            | 1748 (6.41)              | 426 (16.09)           |
| Nausea                                           | 1274 (4.67)              | 73 (2.79)             |
| Vomiting                                         | 219 (0.80)               | 53 (2.03)             |
| Chest pain                                       | 1108 (4.06)              | 77 (2.96)             |
| Abdominal pain                                   | 810 (2.97)               | 34 (1.30)             |
| Diarrhea                                         | 758 (2.78)               | 29 (1.11)             |
| Dizziness/Vertigo                                | 512 (1.87)               | 30 (1.15)             |
| Loss of smell                                    | 481 (1.76)               | 22 (0.83)             |
| Loss of taste                                    | 413 (1.51)               | 26 (0.98)             |
| Convulsions                                      | 210 (0.77)               | 10 (0.38)             |
| Paresis                                          | 177 (0.64)               | 13 (0.50)             |
| Palegia                                          | 84 (0.30)                | 11 (0.42)             |
| Dermatitis                                       | 78 (0.28)                | 7 (0.27)              |
| **Type of comorbidity**                          |                          |                       |
| Hypertension                                     | 3448 (12.65)             | 499 (18.92)           |
| Cardiovascular disease                           | 2077 (7.62)              | 284 (10.77)           |
| Diabetes                                         | 2008 (7.36)              | 277 (10.50)           |
| Cancer                                           | 557 (2.04)               | 88 (3.34)             |
| Chronic kidney disease                           | 479 (1.75)               | 96 (3.64)             |
| Asthma                                           | 310 (1.13)               | 26 (0.99)             |
| Other chronic lung diseases                      | 493 (1.80)               | 60 (2.27)             |
| Chronic neurologic diseases                      | 140 (0.51)               | 23 (0.87)             |
| Chronic blood disease                            | 118 (0.43)               | 13 (0.59)             |
| Chronic liver disease                            | 96 (0.35)                | 19 (0.72)             |
Table 1 (continued)

| Variable                     | Total N (%) (n = 27,256) | Died N (%) (n = 2646) |
|------------------------------|--------------------------|-----------------------|
| Immunodeficiency             | 36 (0.13)                | 2 (0.08)              |
| HIV/AIDS                     | 19 (0.07)                | 1 (0.04)              |
| Number of comorbidities, n (%) |                          |                       |
| 1                            | 4968 (18.22)             | 654 (24.79)           |
| 2                            | 1699 (6.2)               | 255 (9.67)            |
| ≥3                           | 369 (1.35)               | 58 (2.20)             |
| Saturation of O2 < 93        | 17,799 (65.30)           | 2194 (82.84)          |
| Case definition              |                          |                       |
| Confirmed case               | 12,917 (47.39)           | 1692 (63.95)          |
| Probable case                | 9136 (33.52)             | 663 (25.06)           |
| Suspected case               | 5203 (19.09)             | 291 (11)              |
| Intensive care unit (ICU) admission | 5190 (19.04)         | 1111 (41.99)          |
| Intubation                   | 3163 (11.60)             | 1004 (37.94)          |

Fig. 1  Distribution of hospitalization and death cases from COVID-19 at the county scale in Kermanshah province from February 20, 2020-February 19, 2021 (782 non-resident patients in Kermanshah Province were excluded from the map): A: the number of hospitalization, B: the number of hospitalization per 100,000 population by county, C: the number of deaths, D: the number of deaths per 1,000,000 population by county
in 100,000 population, ranging from 425 per 100,000 to 2472 per 100,000 in Dalahu and Paveh counties, respectively (Fig. 1B and Additional file 1: Table S1). During the 1-year period, the frequency of death among patients hospitalized with COVID-19 in Kermanshah Province was 1280 per 1,000,000 population. The lowest and highest frequency of death among patients hospitalized with COVID-19 was 388 per 1,000,000 and 2472 per 1,000,000 population in Salas-e Babajani and Paveh counties, respectively (Fig. 1D and Additional file 1: Table S1). The highest frequency of hospital admissions and deaths was seen in three referral hospitals: Farabi (14.11% of hospital admissions and 11.88% of deaths), Imam Reza (12.38% of hospital admissions and 6.93% of deaths) and Golestan (11.73% of hospital admissions and 19.45% of deaths). The highest frequency of ICU admission was seen in Imam Ali Hospital (416 cases, 58.84%). In addition, the highest frequency of ICU deaths was seen in Shahid Chamran hospital in Kangavar county (46 cases, 71.88%) (more details in Additional file 1: Table S2).

**Clinical outcomes**

Of the 27,256 hospitalized COVID-19 patients, 2646 died (9.71%), including 1533 (57.94%) female and 1113 (42.06%) male patients. The deceased had a mean age of 64.97 ± 19.97 years compared to those who hospitalized (53.34 ± 22.74) (not shown in the table). In-hospital mortality was 3.85%, 9.07%, 15.23%, 59.26% and 12.59% in the age group < 15 years, 15–45 years, 45–60 years, 60–85 years, and > 85 years, respectively. The ICU admission rate was 19.04% (5190 patients) with a mortality rate of 41.99%. In addition, 11.60% (3163 patients) required invasive mechanical ventilation of whom 37.94% died. Other findings are shown in Table 1.

The median and mean length of hospital stay among COVID-19 survivors patients was 4 (interquartile range [IQR] 1–6) and 4.86 (SD: 5.11) days, respectively. The median and mean length of hospital stay among COVID-19 survivors patients was 4 (IQR: 1–8) and 6.1 (SD: 6.71) days, respectively (Additional file 1: Table S3).

**Epidemiological curve**

Kermanshah Province experienced three waves of COVID-19 infection considering the hospitalization and mortality rates in one year. The daily distribution of hospital admissions and in-hospital mortality is shown in Fig. 2. The first wave was between early March and early May 2020. The largest number of daily admissions and in-hospital mortality was 1280 and 189 cases in the first wave and 189 and 6 cases in the second wave, respectively. The second and third waves hit dramatically in late May and early September followed by a progressive decrease with very few patients admitted in late August and late December. The largest number of daily admissions and in-hospital mortality was 488 and 16 cases in the second wave and 1244 and 38 cases in the third wave, respectively.

**Predictors of in-hospital all-cause mortality**

A multivariable logistic regression revealed that odds of death among patients ≥ 85 years was significantly greater than among patients < 15 years (adjusted odds ratio [aOR] 4.79, 95% confidence interval [CI] = 3.43–6.71, p < 0.001). Male sex was also associated with increased odds of in-hospital mortality (aOR 1.20, 95% CI 1.07–1.35, p = 0.002). The patients with SpO2 ≤ 93% using a pulse oximeter had 2.7 (95% CI 2.34–3.16, p < 0.001) times higher odds of mortality compared to those with SpO2 > 93% in the multivariable model. Patients with one (aOR 1.38, 95% CI 1.21–1.59, p = 0.04), two (aOR 1.56, 95% CI 1.27–1.92, p = 0.001) or more (aOR 1.50, 95% CI 1.04–2.17, p = 0.03) comorbidities had higher odds of in-hospital death compared to those without comorbidities. Multivariable regression showed increased odds of mortality rate with respiratory distress (aOR 1.40, 95% CI 1.22–1.61, p < 0.001), loss of consciousness (aOR 1.81, 95% CI 1.45–2.25, p < 0.001), and anorexia (aOR 1.36, 95% CI 1.09–1.70, p = 0.006) on admission. Having cough (aOR 0.82, 95% CI 0.72–0.93, p = 0.003) and headache (aOR 0.70, 95% CI 0.50–0.97, p = 0.03) decreased the odds of death. There was a statistically significant association between COVID-19 death and ICU admission (aOR 4.35, 95% CI 3.80–4.97, p < 0.001) and intubation (aOR 11.09, 95% CI 9.58–12.84, p < 0.001). The risk factors for in-hospital are summarized in Table 2.

**Discussion**

This study investigated the epidemiological, demographic, and clinical characteristics and outcomes of COVID-19 patients hospitalized in all hospitals and healthcare facilities of Kermanshah Province, west of Iran during the first year of the pandemic. In the present study, 27,256 patients with SARS-CoV-2 infection were admitted to the hospitals. Our results show that the in-hospital mortality rate in the hospitalized patients with COVID-19 was 9.71% (2646 of 27,256). In-hospital mortality rate varied between previous studies conducted in Iran, reporting the earlier mentioned 8.5% in an Ardabil Province cohort[14], 27.62% in a Mashhad city [15], and about 10% in a Tehran Province cohort. In a nationwide study in Iran between 20 February and 20 April 2020, the cumulative risk for in-hospital mortality in 30 days was 24.4% (23,367 of 5693 patients) [16]. In a nationwide study in Brazil including 254,288 hospitalized patients with PCR confirmed COVID-19, in-hospital mortality was 38% (87,515 of 232 036 patients); moreover, 59% (4002 of 79,687) of the patients were admitted to the ICU,
and 80% (36,046 of 45,205) required mechanically ventilated [17]. Mortality among hospitalized COVID-19 patients in USA [18], Oman [19], India [20] is reported 21.4%, 26% and 13.72%, respectively. Although the criteria for hospital admission, case definitions, patient characteristics, etc. may vary among countries, the mortality of COVID-19 patients could be influenced by the mismatch between demand and supply, resource capacity, and lack of trained ICU staff.

In our study, the median (IQR) length of hospital stay was 4 (1–6) and 4 (1–8) day in survivors and non-survivors, respectively, which was shorter than those reported in large cohorts in other countries such as Indonesia [21], Belgian [22] and Germany [23]. The presence of comorbidities, patient age, delayed access to healthcare, and hospital discharge criteria can be responsible for this difference. Iran was one of the countries that experienced the highest number of COVID-19 cases and deaths. Therefore, in order to increase the capacity of the hospitals in response to pandemic, especially at the peak of COVID-19 outbreaks, a number of patients were discharged from hospital with partial recovery and moved to home care.

Our findings are in line with two previous cohort studies, which reported cough was associated with good prognosis in patients hospitalized with COVID-19 [24, 25]. Possible reason could be role of earlier health seeking behavior in patients with cough that contributing to more favorable outcomes for patients. Nevertheless, these findings conflict with several other studies which found cough is an adverse predictor of case fatality or severe disease [26]. It is important to note that we didn’t specify the nature of cough, thus these results should be interpreted with caution.

Fig. 2 Number of SARS-CoV-2 hospitalized A and death B cases from 20 February 2020 to 19 February 2021 in Kermanshah Province, Iran
| Variable | Category | Total number (%) | Crude OR | P value | Adjusted OR (95% CI)* | P value |
|----------|----------|------------------|----------|---------|-----------------------|---------|
| Sex      | Male     | 14,648 (53.74)   | 1.20 (1.11–1.31) | < 0.001 | 1.20 (1.07–1.35)     | 0.002   |
|          | Female   | 12,608 (46.26)   | 1        |         | 1                     |         |
| Age Group| <15      | 2122 (7.79)      | 1        |         | 1                     |         |
|          | 15–45    | 6635 (24.34)     | 0.74 (0.58–0.94) | 0.01   | 0.81 (0.58–1.33)     | 0.23    |
|          | 45–60    | 5893 (21.62)     | 1.45 (1.16–1.81) | < 0.001 | 1.43 (1.04–1.96)     | 0.02    |
|          | 60–85    | 11,002 (40.37)   | 3.29 (2.68–4.05) | < 0.001 | 2.88 (2.14–3.87)     | < 0.001 |
|          | ≥ 85     | 1604 (5.88)      | 5.18 (4.11–6.54) | < 0.001 | 4.79 (3.43–6.71)     | < 0.001 |
| Dwelling place | Outside provincial capital and other provinces | 13,769 (50.52) | 0.79 (0.58–0.68) | < 0.001 | 1.14 (1.01–1.29)     | 0.03    |
|          | Provincial capital | 13,487 (49.48) | 1        |         | 1                     |         |
| History of contact with a case of COVID-19 | Yes | 12,449 (45.67) | 1.32 (1.22–1.44) | < 0.001 | 0.89 (0.79–1.01)     | 0.08    |
|          | No       | 14,807 (54.33)   | 1        |         | 1                     |         |
| Length of stay in hospital (Day) | Yes | 2159 (7.92) | 12.40 (11.24–13.68) | < 0.001 | 11.09 (9.58–12.84) | < 0.001 |
|          | No       | 25,097 (92.08)   | 1        |         | 1                     |         |
| Intubation | Yes | 4079 (14.97) | 5.27 (4.83–5.75) | < 0.001 | 4.35 (3.80–4.97)     | < 0.001 |
|          | No       | 23,177 (85.03)   | 1        |         | 1                     |         |
| Number of comorbidities | 1 | 4314 (18.31) | 1.58 (1.44–1.74) | < 0.001 | 1.38 (1.21–1.59)     | 0.04    |
|          | 2        | 1444 (6.13)      | 1.88 (1.63–2.17) | < 0.001 | 1.56 (1.27–1.92)     | 0.001   |
|          | ≥ 3      | 374 (1.59)       | 1.86 (1.43–2.40) | < 0.001 | 1.50 (1.04–2.17)     | 0.03    |
|          | No       | 17,430 (73.98)   | 1        |         | 1                     |         |
| Body temperature (°C) | Yes | 10,258 (37.64) | 1.81 (1.67–1.97) | < 0.001 | 1.75 (1.54–2.00)     | < 0.001 |
|          | No       | 16,998 (62.36)   | 1        |         | 1                     |         |
| Hospital | Referral hospitals | 10,258 (37.64) | 1.81 (1.67–1.97) | < 0.001 | 1.75 (1.54–2.00)     | < 0.001 |
|          | Other hospitals | 16,998 (62.36) | 1        |         | 1                     |         |
| Case definition | Confirmed case | 12,917 (47.39) | 2.54 (2.23–2.89) | < 0.001 | 2.17 (1.78–2.65)     | < 0.001 |
|          | Probable case | 9136 (33.52) | 1.35 (1.14–1.52) | < 0.001 | 1.19 (0.95–1.48)     | 0.11    |
|          | Suspected case | 5203 (19.09) | 1        |         | 1                     |         |
| Saturation of O2 | < 93 | 15,605 (57.25) | 4.03 (3.63–4.47) | < 0.001 | 2.72 (2.34–3.16)     | < 0.001 |
|          | ≥ 93     | 11,651 (42.75)   | 1        |         | 1                     |         |
| Symptoms | Fever    | 7785 (28.89)     | 0.60 (0.59–0.66) | < 0.001 | 1.07 (0.92–1.24)     | 0.35    |
|          | Cough    | 10,512 (38.57)   | 0.61 (0.56–0.67) | < 0.001 | 0.82 (0.72–0.93)     | 0.003   |
|          | Respiratory distress | 15,981 (58.63) | 1.87 (1.71–2.04) | < 0.001 | 1.40 (1.22–1.61)     | < 0.001 |
|          | Loss of consciousness | 1322 (4.55) | 5.07 (4.48–5.73) | < 0.001 | 1.81 (1.45–2.25)     | < 0.001 |
|          | Convulsions | 200 (0.73) | 0.48 (0.25–0.92) | 0.02 | 0.77 (0.33–1.83)     | 0.56    |
|          | Abdominal pain | 776 (2.97) | 0.40 (0.28–0.57) | < 0.001 | 0.75 (0.46–1.24)     | 0.27    |
|          | Vomiting | 1166 (44.66)     | 0.41 (0.31–0.55) | < 0.001 | 0.87 (0.60–1.26)     | 0.49    |
|          | Anorexia | 1784 (6.83)      | 0.89 (0.76–1.06) | 0.19 | 1.36 (1.09–1.70)     | 0.006   |
|          | Headache | 1488 (5.76)      | 0.37 (0.28–0.48) | < 0.001 | 0.70 (0.50–0.97)     | 0.03    |
|          | Muscle pain | 6485 (23.79) | 0.72 (0.65–1.80) | 0.21 | –                     |        |
|          | Loss of taste | 387 (1.42) | 0.66 (0.44–1.99) | 0.46 | –                     |        |
|          | Nausea   | 1201 (4.60)      | 0.57 (0.44–1.41) | 0.39 | –                     |        |
|          | Dizziness/vertigo | 482 (1.87) | 0.58 (0.40–1.85) | 0.51 | –                     |        |
|          | Paresis  | 164 (0.63)       | 0.76 (0.43–1.35) | 0.35 | –                     |        |
|          | Plegia   | 73 (0.28)        | 1.54 (0.83–3.01) | 0.26 | –                     |        |
|          | Dermatitis | 71 (0.27) | 0.97 (0.44–2.13) | 0.95 | –                     |        |
|          | Chest pain | 1031 (3.99) | 0.71 (0.56–1.90) | 0.55 | –                     |        |
|          | Diarrhea | 729 (2.79)       | 0.36 (0.25–1.53) | 0.43 | –                     |        |

*Odds Ratio for each variable adjusted for other variables in model
CI: confidence interval, OR: odds ratio
Critical COVID-19 may be associated with acute respiratory distress syndrome (ARDS), liver damage, heart failure, renal failure, shock cardiac and septic shock [27]. Hence, ICU admission plays a dominant role in the care of COVID-19 patients and reducing the mortality. In a Chinese study, mortality rate of outside ICUs in patients with COVID-19 was 30% [28], and it was 13% in patients hospitalized with COVID-19 in Brazil [13]. Previous studies from Iran have reported a range of 46% to 88% [14, 15, 29]. The results of our study showed that mortality rate outside of ICU (60%) were higher compared to the mentioned studies. Although, the increased number of critically ill patients during COVID-19 peaks increases the demand for critical care, health authorities need to increase ICU beds, particularly in referral hospitals, to avoid delays in admission and provide mechanical ventilators in abundance to treat the patients who present with respiratory distress.

Advanced age is an independent risk factor for COVID-19 mortality [30]. A recent meta-analysis found that adults above 65 years were five times more likely to become critical or die [31]. In the present study, adjusted in-hospital mortality estimates associated with COVID-19 were the lowest in the age group 0–15 years and increased almost linearly with age from 2.88- fold odds (95% CI 2.14–3.87, P < 0.001) in patients 60–85 years to 4.79- fold odds (95% CI 3.43–71.6, P < 0.001) in those ≥ 85 years. Some studies showed that advanced age was associated with a compromised immune system and an increase in chance of co-morbidities resulting in a higher COVID mortality, similar to SARS and MERS [32, 33]. In the present study, more than half of the hospitalized cases were male patients (53.74%), which was consistent with other studies [34, 35]. It was also found that male gender significantly increased mortality with an adjusted odds ratio of 1.20 (95% CI: 1.07–1.35). This finding was also consistent with other studies [36, 37]. The lower incidence of SARS-CoV-2 among women may be related to the physiology of human (X chromosome and sex hormones) which have been reported to play a major role in innate and adaptive immunity [38].

Interestingly, the in-hospital mortality rate of COVID-19 in pregnant women was very low in our study (1 case per 259 pregnant women). A multicenter cohort study of COVID-19 in hospitalized pregnant women from USA evaluated 44(69%) pregnant women with severe disease and 20(31%) with critical disease [39]. The authors concluded that pregnant women might experience similar, or even lower, rates of severe or critical COVID-19 than non-pregnant patients. They did not report any deaths. Similarly, a systematic review found that the mortality of the pregnant women with COVID-19 was lower than that of overall COVID-19 patients [40]. In addition, a universal screening study in Mexico showed no difference in perinatal outcomes between SARS-CoV-2 positive and negative pregnant women, except for preeclampsia [41]. This is possible that younger pregnant women have a lower risk of underlying diseases. Overall, little evidence is available on COVID-19 in pregnant women and further research is warranted.

Nowruz, the celebration of Iranian New Year, starts on March 20/21 and is considered the most important holiday in Iran. The outbreak of COVID-19 in Iran coincided with the end of the Persian year which is characterized by a shopping spree and crowded streets. On the other hand, Nowruz holidays are a time for Iranians to make family gatherings, ceremonies, and travels. Thus, Nowruz holidays aggravated the COVID-19 crisis in Iran and the first wave of the epidemic started in the mid-spring [42]. Following the increase in the number of new cases of COVID-19, the government imposed some restrictions such as travel banning, closure of the schools and universities, a ban on Friday prayers and working from home. Considering that the spread of COVID-19 infection has never been completely under control in Iran, Kermanshah Province experienced other two major peaks in hospitalized and mortality cases with a slight delay compared to some provinces in mid-summer, and mid-autumn. In line with other reports from Iranian health officials, our findings also showed an increase in the total number of hospitalizations and deaths during the third wave compared to the previous waves [32]. The highest daily mortality from COVID-19 in Iran and Kermanshah Province in 2020 was 486 (on 2020-11-16) [43] and 38 cases (on 2020-11-08), respectively. In November and December 2020, the daily number of mortality for COVID-19 exceeded 400 cases during 28 days in Iran [32]. This high rate of mortality could be associated with several factors such as reduced observance of health protocols and social distancing, failure to enforce interventions due to public fatigue and economic problems, increased travel in the late summer, and lack of specific protocols for travel restrictions. It is worth noting that the third peak coincided with the arrival of B.1.1.413 variants of SARS-CoV-2 in the country which is more contagious than the alpha variant [44]. According to the national vaccination document, vaccination against COVID-19 started on February 21, 2021 with priority given to the health professionals, elderly population, and vulnerable and high-risk groups. Nevertheless, a combination of limited vaccine availability and slow vaccination rate leads to a longer epidemic and may even result in new SARS-CoV-2 variants, which can compromise immunity, raise concerns about vaccine effectiveness, and increase the crisis worldwide.
A strength point of this study was its large sample size including confirmed, probable, and suspected COVID-19 cases; therefore, it may provide a comprehensive picture of hospitalized patients with COVID-19 infection. Our study also suffered from several limitations. First, some variables such as the body mass index, treatments administered in the hospital and laboratory findings were not provided, which limited our ability to draw a conclusion on mortality based on the data. Second, the comorbidity data were based on self-reports and it was not possible to verify their validity. Finally, attention should be paid to variations in patient management; however, all hospitals and healthcare facilities for COVID-19 patients in Kermanshah Province were included in the study.

Conclusions
In summary, about half of patients hospitalized with COVID-19 in Kermanshah Province were over 60 years of age. Of patients in this cohort, 19.04% of the patients were admitted to ICU of whom 41.99% died. Moreover, 11.60% required invasive mechanical ventilation, of whom 37.94% died. Overall, the in-hospital mortality rate was 9.71%. Although patients requiring intubation were more likely to die, the beneficial effects of intubation on patient treatment and management should not be ignored. Male gender, advanced age, comorbidities significantly increased the odds of mortality. Respiratory distress, SpO2 < 93, loss of consciousness, and anorexia were the symptoms most strongly associated with higher odds of mortality, suggesting that they have a high value in clinical assessment of the severity of COVID-19. As expected, due to the admission of patients with more serious and complex medical conditions in referral hospitals, the odds ratio of COVID-19 related mortality was higher in these hospitals compared other hospitals. Nonetheless, this finding requires the immediate attention of health officials to provide better medical services and preventive interventions for off-center healthcare facilities.

Abbreviations
MCMC: Medical care monitoring center; SpO2: Peripheral oxygen saturation; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; ICUs: Intensive care unit; KUMS: Kermanshah University of Medical Sciences; BPs: Blood pressures; MOHME: Ministry of Health and Medical Education; CT scan: Computed tomography; MCMC: Medical care monitoring center.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12879-022-07312-7.

Acknowledgements
We give our respectful thanks to the healthcare workers of Kermanshah Province fight COVID-19 pandemic. We thank the staff of the Medical care monitoring center (MCMC) for their generous assistance. We also like to acknowledge the cooperation of Vice Chancellor for Treatment of Kermanshah University of Medical Sciences. This article was part of a MD dissertation (by Nazanin Sayad) supported by Guilan University of Medical Sciences (GUMS).

Authors’ contributions
BS, NS, EH and RK designed the study. NS collected the data. FKS and FN conducted the statistical analyses. AB, ZR and BD drafted the first version of the paper. All co-authors made a substantial contribution to interpreting data, critically revised the article, and approved the final version, including the authorship list.

Funding
The Research Council of Guilan University of Medical Sciences provided financial support (Grant No. 123) to help the researcher to collect data from electronic medical records. There were no roles of the funding body in the design of the present study, or collection, analysis, and interpretation of data, or in writing the manuscript. All authors read and approved the final manuscript.

Availability of data and materials
All data generated or analysed during this study are included in this published article.

Declarations
Ethics approval and consent to participate
The protocol was approved by the Ethics Committee of Guilan University of Medical Sciences, code number: IR.GUMS.REC.1399.489. The requirement for informed consent was waived because of the retrospective nature of the study by the Ethics Committee of Guilan University of Medical Sciences. All methods were carried out in accordance with relevant guidelines and regulations.

Consent for publication
Not applicable.

Competing interests
All the authors declare no competing interest.

Author details
1. Department of Infectious Diseases, Faculty of Medicine, Guilan University of Medical Sciences, Rasht, Iran. 2. Infectious Diseases Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. 3. Research Center for Environmental Determinants of Health, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. 4. Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. 5. Department of Clinical Biochemistry, Medical School, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Received: 28 July 2021   Accepted: 23 March 2022
Published online: 31 March 2022

Additional file 1: Table S1. Frequency of hospital admissions and deaths by county in Kermanshah Province, Iran, during the first year COVID-19 pandemic. Table S2. Outcomes for patients hospitalized with COVID-19 based on hospital. Table S3. Duration from hospitalization to discharge/ death for patients hospitalized for COVID-19 based on hospital.

References
1. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. Geneva: World Health Organization; 2020.
2. Sisó-Almirall A, Brito-Zerón P, Conangla Ferrín L, Kostov B, Moragas Moreno A, Mestres J, et al. Long COVID-19: proposed primary care clinical guidelines for diagnosis and disease management. Int J Environ Res Public Health. 2021;18(8):4350.
3. Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paiandre J, et al. Estimating the burden of SARS-CoV-2 in France. Science. 2020;369(6500):208–11.
4. Avatef Fazeli M, Rezaei L, Javadirad E, Iranfar K, Khosravi A, Amini Saman J, et al. Increased incidence of rhino-orbital mucormycosis in

10.1186/s12879-022-07312-7
an educational therapeutic hospital during the COVID-19 pandemic in western Iran. An observational study. Mycoses. 2021;64(11):1366–77.

5. Yavarian J, Shafei-Jandaghi N-Z, Sadeghi K, Malekshahi SS, Salimi V, Nejat A, et al. First cases of SARS-CoV-2 in Iran, 2020: case series report. Iran J Public Health. 2020;49(8):1564.

6. Poursho S, Davvishian M, Mohammadi Z, Shanayrad A, Delavari A, Bahadorinomaref A, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Lancet Infect Dis. 2021;21(4):473–81.

7. Mohammazadeh N, Shahrizy M, Nasri E. Iran’s success in controlling the COVID-19 pandemic. Infect Control Hosp Epidemiol. 2020;41(11):1359–60.

8. Sayab B, Khodaramhi R, Najafi F, Miladi R, Afshar ZM, Mansourf S, et al. Efficacy and safety of ososofubur/velpatasvir versus the standard of care in adult hospitalized with COVID-19: a single-centre, randomized controlled trial. J Antimicrob Chemother. 2021. https://doi.org/10.1093/jac/dkaa152.

9. Schoeni RF, Wiemers EE, Seltzer JA, Langa KM. Association between risk factors for complications from COVID-19, perceived chances of infection and complications, and protective behavior in the US. JAMA Netw Open. 2021;4(3):e213984.

10. Pirio L, Cottenet J, Mariet A-S, Borniaud P, Blot M, Tubert-Bitter P, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021;9(3):251–9.

11. Yegorov S, Goremykina M, Ivanova R, Good SV, Babenko D, Shvetsov A, et al. Epidemiology, clinical characteristics, and virologic features of COVID-19 patients in Kazakhstan: a nationwide retrospective cohort study. Lancet Reg Health-Eur. 2021;4:100096.

12. Kim S-W, Kim S-M, Kim YK, Kim J-Y, Lee Y-M, Kim B-O, et al. Clinical characteristics and outcomes of COVID-19 cohort patients in Daegu metropolitan city outbreak in 2020. J Korean Med Sci. 2021. https://doi.org/10.3346/jkms.2021.36.e12.

13. Marcolino MS, Ziegelmann PK, Souza-Silva MV, Nascimento I, Oliveira LM, Monteiro LS, et al. Clinical characteristics and outcomes of patients hospitalized with COVID-19 in Brazil: Results from the Brazilian COVID-19 registry. Int J Infect Dis. 2021. https://doi.org/10.1016/j.ijid.2021.01.019.

14. Adham D, Habibzadeh S, Ghobadi H, Jain S, Abbasi-Ghahramanloo A, Moradi-Asli E. Epidemiological characteristics and mortality risk factors among COVID-19 patients in Ardabil, Northwest of Iran. BMC Emerg Med. 2021;21(1):1–6.

15. Goshayeshi L, Akbari Rad M, Bergquist R, Allhayari A, Hashemzadeh K, Hoseini B. Demographic and clinical characteristics of severe COVID-19 infections: a cross-sectional study from Mashhad University of Medical Sciences. Iran BMC infectious diseases. 2021;20(1):1–8.

16. Jalili M, Payandemehr P, Saghaei A, Sani HN, Saffikhani H, Kolivand P. Characteristics and mortality of hospitalized patients with COVID-19 in Iran: a National Retrospective Cohort Study. Ann Intern Med. 2021;174(1):125–7.

17. Ranzani OT, Bastos LS, Gelli JGM, Marchesi JF, Baião F, Hamacher S, et al. Characterization of the first 250,000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data. Lancet Respir Med. 2021;9(4):407–18.

18. Fried MW, Crawford JM, Mospan AR, Watkins SE, Hoffmann F, Hoffmann M, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: a hospital-based retrospective cohort study. Lancet Reg Health Western Pacific. 2021;9:100108.
with or without mild/moderate symptoms: Results from universal screening in a tertiary care center in Mexico City, Mexico. PLoS One. 2021;16(4):e0249584.

42. Kaffashi A, Jahani F. Nowruz travelers and the COVID-19 pandemic in Iran. Infect Control Hosp Epidemiol. 2020;41(6):1121.

43. https://per.euronews.com/2021/04/26/iran-hit-daily-death-toll-record-amid-pandemic-new-wave. Accessed 26 Apr 2021.

44. Fattahi Z, Mohseni M, Beheshtian M, Jafarpour A, Jalalvand K, Keshavarzi F, et al. Disease waves of SARS-CoV-2 in Iran closely mirror global pandemic trends. MedRxiv. 2021;8:661277.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.